Dar Bioscience Inc   (DARE)
Other Ticker:  
Price: $0.5499 $-0.02 -4.199%
Day's High: $0.5899 Week Perf: 27.85 %
Day's Low: $ 0.54 30 Day Perf: 69.2 %
Volume (M): 576 52 Wk High: $ 1.15
Volume (M$): $ 317 52 Wk Avg: $0.66
Open: $0.58 52 Wk Low: $0.27

 Market Capitalization (Millions $) 50
 Shares Outstanding (Millions) 91
 Employees 10
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) -26
 Capital Exp. (TTM) (Millions $) 0

Dar Bioscience Inc
Dar Bioscience Inc., also known as Dar' Bioscience, is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company is focused on developing and commercializing innovative products for women's reproductive health. Dar' Bioscience was founded in 2015 and became a public company in 201

The company is led by CEO Sabrina Martucci Johnson, who has more than 20 years of experience in healthcare and biopharmaceutical industries. Johnson is supported by a team of experienced professionals, including researchers, clinical trial specialists, business leaders, and medical doctors.

Dar' Bioscience is developing a portfolio of product candidates designed to address unmet needs in women's reproductive health, including contraception, fertility, and menopause. The company's lead product candidate is Ovaprene, a hormone-free, monthly contraceptive ring designed to prevent pregnancy for up to three months. Ovaprene is currently in Phase 2 clinical trials and has the potential to provide women with a noninvasive and discrete contraceptive option.

In addition to Ovaprene, Dar' Bioscience is also developing other innovative product candidates, including:

- Sildenafil Cream, a topical treatment for female sexual arousal disorder that is currently in Phase 3 clinical trials
- D-Ovulation, a handheld, battery-operated device that tracks ovulation by measuring hormone levels that is currently in Phase 2 clinical trials
- Vaginal tamoxifen, a treatment for vaginal dryness in women with breast cancer that is currently in Phase 1 clinical trials

Dar' Bioscience has a strong intellectual property portfolio that includes multiple patents and patent applications covering its product candidates and technology platforms. The company is also actively pursuing strategic partnerships and collaborations with other companies and organizations to advance its product candidates and bring them to market.

Overall, Dar' Bioscience is a dynamic and innovative biopharmaceutical company that is dedicated to improving women's reproductive health through the development of safe and effective products. With a strong pipeline of product candidates and a committed team of professionals, the company is well positioned to address unmet needs in this important area of healthcare.

   Company Address: 3655 Nobel Drive San Diego 92122 CA
   Company Phone Number: 926-7655   Stock Exchange / Ticker: DARE
   DARE is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Dare Bioscience Bolsters Women's Health with Groundbreaking Advancements and Treatment Options

Published Thu, Feb 22 2024 1:01 PM UTC

Dare Bioscience: Advancements in Women's Health and Treatment OptionsDare Bioscience, a leading healthcare company focused on women's health, recently made significant strides in their ongoing research and development efforts. The company presented groundbreaking data at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting, showcasing the ...

Clinical Study

Transforming the Paradigm of Female Sexual Arousal Disorder: Unraveling the Potential of Sildenafil Cream, 3.6%.

Published Wed, Jan 31 2024 1:00 PM UTC

The gap in the healthcare industry concerning the treatment of Female Sexual Arousal Disorder (FSAD) is glaringly wide with no FDA-approved treatment for the condition, leaving a significant population of women globally to grapple with their sexual health and wellness. Dare Bioscience?s successful End-of-Phase 2 meeting with the FDA about their groundbreaking product, Silden...

Clinical Study

DARE Biosciences' DARE-LARC1: Revolutionizing Women's Health and Beyond

Published Thu, Jan 4 2024 1:00 PM UTC

DARE Biosciences' Breakthrough Technology Opens New Doors for Women's Health and BeyondIn an exciting development, DARE Biosciences' revolutionary DARE-LARC1 platform technology has achieved proof-of-concept for a transformative device. This groundbreaking device not only holds immense potential for improving women's health but also offers promising avenues for treating a br...

Clinical Study

Dare Bioscience Makes Waves with Potential First-in-Category Treatment for Primary Dysmenorrhea

Published Wed, Dec 20 2023 1:00 PM UTC

Dare Bioscience, a leading pharmaceutical company, recently announced positive topline pharmacokinetic and exploratory efficacy results from the DARE-PDM1 Phase 1 clinical study. These results support the continued clinical development of DARE-PDM1, positioning it as a potential first-in-category treatment for primary dysmenorrhea. Additionally, we will examine Dar...

Financing Agreement

Dar Bioscience Receives Funding Award from NIH to Advance Groundbreaking Treatment for Preterm Birth

Published Wed, Dec 13 2023 1:00 PM UTC

Dar Bioscience Inc, a leading pharmaceutical company, is developing a groundbreaking treatment called DARE-PTB1 to mitigate the risk of preterm birth. Currently, there are no FDA-approved treatment options available for this condition. Preterm birth, defined as giving birth before completing 37 weeks of gestation, poses numerous health risks for both the baby and the mo...


Dar Bioscience Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com